David Badawi - 21 Sep 2022 Form 4/A - Amendment Insider Report for Sight Sciences, Inc. (SGHT)

Role: Chief Technology Officer, Director
Signature: /s/Jeremy Hayden, Attorney-in-Fact for David Badawi
Issuer symbol: SGHT
Transactions as of: 21 Sep 2022
Net transactions value: $0
Form type: 4/A - Amendment
Filing time: 30 Dec 2025, 16:11:01 UTC
Date Of Original Report: 21 Sep 2022
Previous filing: 11 Feb 2022
Next filing: 05 Jan 2023
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Badawi David	Chief Technology Officer, Director	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVE., SUITE 100, MENLO PARK	/s/Jeremy Hayden, Attorney-in-Fact for David Badawi	30 Dec 2025	0001870825

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	SGHT	Common Stock						1,448,656	21 Sep 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SGHT	Stock Option (Right to Buy)	Options Exercise	$0	-40,000	-48%	$0.000000	42,540	21 Sep 2022	Common Stock	40,000	$0.2300	Direct	F1, F2, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 1,441,196 shares that were previously reported as beneficially owned on the Reporting Person's Form 3 filed on July 14, 2021, as well as 7,460 shares that were acquired by the Reporting Person upon exercise of options prior to the Issuer's completion of the Initial Public Offering in July 2021 that should have been included under Column 2 of Table I of the Form 3 but were inadvertently included as shares underlying options with an exercise price of $0.23 that expire on February 28, 2026 under Column 3 of Table II of the Form 3.
F2	The grant of stock options ("Options") made to the Reporting Person vested and became exercisable as to 25% of the underlying shares on January 1, 2017, and as to the remainder of such shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date, such that all such Options shall be fully vested and exercisable on January 1, 2020.
F3	The original Form 4 filing identified the expiration date of the relevant Options as 01/08/2027. This amendment corrects the expiration date of the relevant Options to February 28, 2026.
F4	Excludes the 7,460 shares that were previously inadvertently included as described in footnote (1) to this Form 4.